• Patients & Families
• Education
• Research
• Community

• Referring Physicians
• Find a Physician
• Departments & Centers
• About URMC

• Libraries
• Alumni
• Giving

URMC » Referring Physicians » URMC Connection » New at URMC

• New at URMC
  • Bone-Anchored Implant Offers Solution for Some with Hearing Loss
  • URMC First to Test New Heart Failure Device
  • URMC Uses Radioactive Microbeads to Combat Liver Cancer
  • Burn and Trauma Services Renamed to Honor Devoted Benefactors
  • FDA Keeps Avandia on the Market
• Breakthroughs
• Facilities and Programs
• Golisano Children's Hospital Connection
• URMC People
• Connect With Us
• CME Calendar

New at URMC

Bone-Anchored Implant Offers Solution for Some with Hearing Loss

Adults and children suffering from certain types of conductive hearing loss, mixed hearing loss, or single-sided deafness have a new treatment option available at the University of Rochester Medical Center. Read more about this hearing loss solution»

URMC First to Test New Heart Failure Device

Cardiologists at the University of Rochester Medical Center were the first in the nation to enroll in a clinical trial for an investigational management system for patients with congestive heart failure. The technology will help patients and their doctors more closely monitor heart health status on a daily basis and potentially could impact the progression of heart failure. Read more about this clinical trial»

Radioactive Microbeads to Combat Liver Cancer

Physicians at URMC recently performed upstate New York’s first radioembolization procedure for primary liver cancer, a technique that combats tumors in patients who cannot be treated with surgery and are awaiting an organ transplant. Learn more about this cancer treatment»

Burn and Trauma Services Renamed to Honor Devoted Benefactors

URMC’s regional burn and trauma services were recently renamed in honor of two local restaurateurs who have raised millions of dollars to support them and share a vision for further developing those services. Learn more about the center »

FDA Keeps Avandia on the Market

Arthur Moss, M.D., director of the Heart Research Follow-up Program, and David Oakes, Ph.D., professor of Biostatistics, participated on an FDA panel that recommended that the controversial diabetes drug Avandia remain on the market as an option for physicians treating patients with Type 2 diabetes. Learn more about Avandia»